LavaTx_RGB.jpg
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 08:00 ET | LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
LavaTx_RGB.jpg
LAVA Reports Second Quarter 2024 Financial Results and Business Update
August 20, 2024 07:30 ET | LAVA Therapeutics N.V.
Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combinationFavorable safety profile for...
LavaTx_RGB.jpg
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 20, 2024 07:30 ET | LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
LavaTx_RGB.jpg
LAVA Announces Annual Meeting of Shareholders
June 10, 2024 07:00 ET | LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
LavaTx_RGB.jpg
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024 07:00 ET | LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on...
LavaTx_RGB.jpg
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
May 21, 2024 07:00 ET | LAVA Therapeutics N.V.
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0 million clinical development milestone from...
LavaTx_RGB.jpg
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
May 06, 2024 16:05 ET | LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on...
LavaTx_RGB.jpg
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
March 20, 2024 07:00 ET | LAVA Therapeutics N.V.
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for...
LavaTx_RGB.jpg
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
March 05, 2024 07:30 ET | LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
LavaTx_RGB.jpg
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
January 25, 2024 07:00 ET | LAVA Therapeutics N.V.
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the...